Nanodelivery carriers increase lung cancer drug bioavailability by 30 times
Scientists at the University of Adelaide have developed a novel nanoparticle delivery system that significantly enhances the bioavailability of lung cancer drugs. This new carrier precisely targets the lungs, increasing drug effectiveness by up to 30 times while minimizing damage to healthy organs. This advancement holds promise for transforming the treatment of lung cancer and other forms of the disease. AI
IMPACT Potential to significantly improve cancer treatment efficacy and reduce side effects.